Fig. 2.
![Fig. 2. Distribution of the duration of neutropenia in patients of group A with prophylactic inhalations (○) and group B without prophylactic inhalations (•). For patients with proven, probable, or possible IA, the number of neutropenic days until an IA infection was suspected or proven are marked with squares ([□] in group A and [▪] in group B).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/93/11/10.1182_blood.v93.11.3654/4/blod41111002x.jpeg?Expires=1724206800&Signature=A~ycfZ9w-xyd2Gn9oxzPWx665BHkPeryvCYpcMZhhO0aYD3x6Ph80G6B14Gio32ZgSELymCmy7BtMPzAlJBehQcO7N3bpynnlgcSoUUj3iKP5n43ctlnSthKyFCDngU4Fx4s9LMaTb5ryx7KsfspmUmAtcr6hbIj2BeumkT05nlYmcEqyTn4LOYr7Lk~W3~U65SmMtVCauVWlJ4CfmIkh5z39yAXNJ~s3qExavbpuakc~pl0tNqWd7Q~QONZO8QnPzlEcNBEm6wggpZCqveswUFJGPLtoGLVZzUc~GQJZbQSLK~q5s2F86LPgjOazoFfJUtUNN6x1T-xYO1Yzl0SsA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Distribution of the duration of neutropenia in patients of group A with prophylactic inhalations (○) and group B without prophylactic inhalations (•). For patients with proven, probable, or possible IA, the number of neutropenic days until an IA infection was suspected or proven are marked with squares ([□] in group A and [▪] in group B).
